News | August 05, 2021
Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Deal for 100 million doses with additional 100 million through 2023
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
The vaccine was 85 percent effective in preventing severe disease across all regions.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
